EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Systemic AL amyloidosis: current approach and future direction

Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, Chakra P Chaulagain

Oncotarget · 2023

DOI: 10.18632/oncotarget.28415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncotarget, 2023. Verfasst von Maroun Bou Zerdan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Frailty, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved but other organs such as gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty, and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidate for HCT due to frailty, old age, multi-organ involvement, renal and heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. In this review, we report the literature on the latest treatment updates of AL amyloidosis and the ongoing clinical trials highlighting the future treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAmyloidosisFrailtyHematopoietic Stem Cell TransplantationParaproteinemiasHumansCongo RedMelphalan

Stichwörter der Autor:innen

amyloidosismanagement

Substanzen

Congo RedMelphalan

Autor:innen und Institutionen

  • Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
  • University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
  • Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon.
  • Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
  • Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA.

Zitieren

APA

Bou Zerdan, M., Nasr, L., Khalid, F., Allam, S., Bouferraa, Y., Batool, S., Tayyeb, M., Adroja, S., Mammadii, M., Anwer, F., Raza, S., & Chaulagain, C. P. (2023). Systemic AL amyloidosis: current approach and future direction. Oncotarget. https://doi.org/10.18632/oncotarget.28415

Vancouver

Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget. 2023. doi:10.18632/oncotarget.28415

BibTeX
@article{BouZerdan2023,
  author = {Bou Zerdan, Maroun and Nasr, Lewis and Khalid, Farhan and Allam, Sabine and Bouferraa, Youssef and Batool, Saba and Tayyeb, Muhammad and Adroja, Shubham and Mammadii, Mahinbanu and Anwer, Faiz and Raza, Shahzad and Chaulagain, Chakra P},
  title = {Systemic AL amyloidosis: current approach and future direction},
  journal = {Oncotarget},
  year = {2023},
  doi = {10.18632/oncotarget.28415}
}
Kostenlos starten →